Abstract. Pancreatic cancer is a major cause of cancer death; and despite advances in the standards of surgery and supportive care, the median and long-term survival rates have not shown similar dramatic improvements. Techniques such as radical surgery alone cannot guarantee a cure. Previous work with conventional chemotherapy and radiotherapy in patients with advanced pancreatic cancer has indicated a role for adjuvant therapy for patients with resectable tumors. The main modalities that have been assessed are based on the Gastrointestinal Tumour Study Group (GITSG) results using 5-fluorouracil chemotherapy, external beam radiation therapy (EBRT), or both. Alternative approaches such as neoadjuvant therapy have been used, which may increase the number of patients suitable for resection; and regional therapy techniques have been used to increase the therapeutic potential by concentrating agents to the tumor bed. The results of single or combination therapy do show some improvement in survival but have been limited in most cases to retrospective nonrandomized series of patients. Therefore the results must be assessed as such. There are several large randomized trials that will deliver definitive answers in the near future as to whether conventional adjuvant therapy is effective. New approaches using novel agents for advanced disease are currently being assessed, and they may eventually identify the most appropriate and effective agents to use for pancreatic cancer in the adjuvant setting.
Pancreatic cancer remains one of the most difficult cancers to treat at the present time. The incidence of the disease is increasing, and it is one of the major causes of cancer death in the Western world, with 5000 deaths per year in the United Kingdom. The overall 5-year survival rate is only 0.4% [1] ; therefore pancreatic cancer represents a significant clinical problem. Improvements in conventional treatment for patients with potentially resectable tumors have contributed to reducing the dismal outlook. They include improved and standardized surgical techniques, advances in supportive care, and referrals of patients to high volume specialized centers [2, 3] . Currently resection rates of up to 14% [4, 5] and operative mortality rates of less than 5% to 10% are being achieved. Nevertheless, the median survival times following surgery are poor: 10 to 18 months with long-term survival rates of 10% to 24% [6 -8] . Most patients are never cured despite optimal surgical intervention.
Regional or extended radical surgery has been advocated as a means of increasing the rate of disease-free margins and hence patient survival. The long-term survival has not proved to be statistically different from that of conventional resection in retrospective series (Table 1) ; however, the proportion of patients undergoing resection is increased. A multicenter randomized trial comparing traditional pancreaticoduodenectomy with a more extensive lymph node resection in 81 patients showed no significant difference in overall survival rates between the two groups [17] , although a recent analysis suggested a benefit for the extended resection (C. Bassi, personal communication). One of the problems of comparing retrospective series of extended resection with historical controls of standard resection is the phenomenon of stage migration. Satake et al. [18] compared the Japanese and UICC systems of staging in a large cohort of patients. Stage for stage the Japanese staging system revealed a better survival, from stage I through stage IV, compared to the UICC system; yet the overall 5-year survival was the same (11%), as the systems were analyzed in identical patients.
The most significant factors in predicting patient outcome are tumor grade, stage, and resection margin status [19 -21] . Patients with negative resection margins and stage I and II disease demonstrate superior long-term survival rates [6, 22] , but the survival of patients with negative resection margins is not as high as might be expected [15, 20, 23] . A major reason for these findings is the pattern of recurrence in pancreatic cancer following potentially curative resection (Table 2 ) and the activity of the tumor. Most tumor recurrences are local, in the peritoneum and liver; local relapses and hepatic metastases are the most frequent cause of death [24] . The early appearance of liver metastases following resection indicates the presence of hepatic micrometastases at the time of surgery [30] . Microscopic peritoneal disease also tends to occur early, in contrast to the later presentation of local failure. The reasons as to why there is recurrence following an apparently successful resection include residual retroperitoneal disease and an aggressive phenotype, as shown by perineural invasion, peritoneal dissemination, hepatic micrometastases, and lymph node involvement. Some authors have advocated extended resection and lymph node dissection as a means of reducing locoregional failure [10] , but extended resection has been associated with a local recurrence rate of 80% [28] . Interestingly, in one study the pattern of failure was similar in patients who had microscopically clear resection margins and those who had only macroscopically clear margins [31] . The results of radical surgery alone and the local and distant patterns of recurrence indicate a need for adjuvant therapy that is effective both locally and systemically.
Case for Adjuvant Therapy
The main purpose of adjuvant therapy is to improve survival in patients with resectable disease, and it should be accompanied by a reasonable quality of life. The level of toxicity is of paramount importance when considering the particular regimen. The rationale for the current range of agents being assessed in the adjuvant setting has been based on the results observed in patients with advanced disease. The standard systemic treatment for advanced pancreatic cancer remains 5-fluorouracil . Among the other drugs tested in advanced pancreatic cancer, mitomycin C is probably the most active. The addition of modulators to 5-FU such as folinic acid, N-phosphonacetyl-L-aspartic acid (PALA), or interferon-␣ have not produced substantial improvements in response rates [32, 33] , although survival rates with multiple modulators-folinic acid ϩ interferon-␣ and folinic acid or mitomycin C ϩ dipyridamole-have shown some encouraging results [34, 35] . A new agent, gemcitabine (a nucleoside analog similar to cytosine arabinoside) has shown a significant survival advantage when compared with 5-FU in a randomized trial. The median survival for gemcitabine patients was 5.7 months compared with 4.4 months for the 5-FU patients. The clinical benefit response rate was used to assess the response to treatment, and this was also significantly greater for the first group of patients [36, 37] . There has been no randomized trial to demonstrate that combination 5-FU therapy is better than 5-FU monotherapy. Several studies have compared combination therapy with untreated controls. Palmer et al. [38] demonstrated a significantly better median survival (33 weeks) with 5-FU, doxorubicin, and mitomycin C (FAM) compared with 15 weeks for untreated controls. Mallinson et al. [39] used 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C regimen and found a median survival of 11 months in treated patients versus 2.2 months in untreated patients. The Mallinson regimen, however, failed to demonstrate any survival advantage compared with a single-agent 5-FU arm in a larger series of patients [40] . Other combinations, such as cisplatin and 5-FU, have resulted in median survival times of 7.6 months [41] but have not been assessed in randomized trials. The superiority of combination therapy has not been proven so far and is associated with significantly greater toxicity than monotherapy.
Radiotherapy has been widely used for treatment of pancreatic cancer; its main disadvantage is that the dose is limited owing to the close proximity of other highly radiosensitive organs. External beam radiotherapy (EBRT) with radiosensitizing 5-FU has been used over the past three decades, although there has never been a randomized trial to compare it with an untreated control arm. Median survival times of 10 to 15 months have been reported, with palliation of symptoms as an important outcome [42, 43] . Intraoperative radiotherapy (IORT) delivers high doses of radiation to the tumor with greater precision than EBRT without damaging adjacent organs. IORT is mainly used to boost EBRT, as results of IORT used alone are not encouraging (median survival 6 months) [44, 45] . Combination of EBRT and IORT has shown some improved survival [45] , although a study comparing EBRT ϩ IORT ϩ 5-FU and EBRT ϩ 5-FU demonstrated no significant survival difference (12 and 13 months, respectively) [46] . Certainly IORT offers good local control and pain relief but cannot be recommended as a standard treatment alone for ad- MST: median survival time; Combined: radical ϩ nonradical. vanced pancreatic cancer. Hepatic irradiation has been advocated to reduce the incidence of hepatic metastases. One study in patients with locally advanced disease demonstrated a decreased incidence of hepatic metastases following prophylactic irradiation but no effect on survival [47] . The considerable toxicity of this approach in combination with chemotherapy was such that one study was terminated prematurely [48] . Radiotherapy and follow-on chemotherapy should enable the control of local disease and systemic destruction of metastases. The Gastrointestinal Tumour Study Group (GITSG) [49] randomized three groups of patients to (1, 2) 60 Gy EBRT (with radiosensitising 5-FU) with or without follow-on weekly 5-FU and (3) 40 Gy EBRT (with radiosensitizing 5-FU) and follow-on 5-FU; the median survival times were 40, 23, and 42 weeks, respectively. A recent study of patients with advanced pancreatic cancer given 44 Gy EBRT and infusion of 5-FU had a median survival of 12.7 months [50] . A randomized trial comparing IORT and IORT ϩ methotrexate/5-FU demonstrated median survival of 4.8 and 8.5 months, respectively [51] . Chemotherapy following radiochemotherapy provides improved survival compared to radiochemotherapy alone for advanced disease.
Regional chemotherapy delivered via the celiac axis increases the dose of drug delivered to the tumor and, when combined with hemofiltration, can deliver three to four times the systemic dose. Median survival times have been reported as 9 to 14 months [52-54] using a variety of regimens such as 5-FU, folinic acid, and cisplatin with response rates as high as 77% [52] in one small study. Occasionally, patients can be converted to resectability following intraarterial infusion [55] . Good control of hepatic metastases has been reported, with disease progression mainly due to local progression or peritoneal deposits.
Adjuvant Chemotherapy
Suprisingly, there have been relatively few studies of chemotherapy (Table 3) alone following surgery and just one randomized controlled trial [57] . This trial used the FAM regimen: 30 patients received chemotherapy following surgery, and 31 patients underwent pancreatoduodenectomy alone. The median survival for the former group was significantly greater than that for the latter (23 vs. 11 months); however, 5-year survival rates were not significantly different. Another study also used the FAM regimen to compare treated and nontreated groups; the 3-year survival rates were statistically similar in these patients [59] . The locoregional recurrence rates were been shown to be no higher than those observed in patients receiving EBRT in the same study. The toxic effects of combination therapy can be considerable. In one study almost half the patients were unable to complete the courses of treatment. Most of these patients required hospitalization for gastrointestinal complications [57] . The relatively few data for chemotherapy alone requires additional randomized studies to confirm its routine use in the adjuvant setting.
Adjuvant Radiotherapy
Both IORT and EBRT have been used singly and together in the postoperative setting (Table 4 ). Their use has been supported by the fact that both seem to reduce the local recurrence rate and achieve good pain relief. Two studies have demonstrated 3-and 5-year survival rates of 53% and 29% when IORT was combined with radical and extended radical resection [66, 67] . Most studies, however, have suggested a survival advantage using either EBRT or EBRT and IORT when compared with IORT alone. Both approaches reduce the local recurrence rate but have no effect on distant metastases; in one study the recurrence rate was 50% less in the IORT group than in the untreated group, but long-term survival was not significantly different between the two groups [29] . Toxicity associated with high doses of IORT can result in vascular damage, septic complications, and gastrointestinal ulcer rates of 14% [68] .
A large randomized phase III trial organized by the European Organisation for Research and Treatment of Cancer (EORTC) comparing adjuvant EBRT and concurrent 5-FU with no adjuvant treatment [65] reported preliminary results of patient survival. A total of 218 patients were randomized; 134 had ductal adenocarcinoma, and the remainder had ampullary tumors, bile duct tumors, and duodenal tumors. The results showed no significant difference in median survival or the 2-year survival rates between the two groups. There were also no significant differences in survival between patients with ductal or ampullary carcinomas. The evidence for the use of radiation therapy as a single agent following resection has not been proven, but good local control and pain relief can be achieved in most patients.
Adjuvant Regional Therapy
The main aim of regional therapy is delivery of high doses of chemotherapeutic agents to the tumor, avoiding damage to the neighboring chemosensitive organs. It is a highly specialized technique, and studies so far have been mainly concentrated on treatment of advanced disease with few adjuvant studies. The first major adjuvant study, by Link et al., used a regimen of 5-FU, folinic acid, mitoxanthrone, and cisplatin via celiac artery infusion in 20 patients following resection. The median survival time was 21 months, and the 2 year survival was 40% [69] .
These results are encouraging, and this approach deserves to be assessed further. The rate of liver metastases is reduced using this approach, but there does not seem to be any effect on the rate of local recurrence. Hepatic infusional therapy has been used to control hepatic metastases. Ishikawa et al. treated patients postoperatively with 4 to 5 weeks of simultaneous infusion of 5-FU via the portal vein and hepatic artery. The 3-year survival rate was 54%, and the deaths due to hepatic metastases were reduced when compared to historical controls [70] . Both approaches were well tolerated in these groups of patients but are associated with a substantial dropout rate.
Neoadjuvant Therapy
Preoperative regimens have been advocated as a means of improving the resection rate and survival, especially in patients with locally advanced disease. The main advantage of preoperative therapy is to avoid the long delays following major pancreatic resection before the patients can begin adjuvant treatment. These benefits should result in more effective irradiation on oxygenated nontraumatized tumor cells and reduce the incidence of positive resection margins and peritoneal tumor cell spread. Studies have reported resection rates as high as 60% [71] , although the size of the tumor may affect the resection rate, as tumors larger than 4 to 5 cm or those that obstruct the portal vein/superior mesenteric vein (SMV) or encase the superior mesenteric artery (SMA) are less likely to be resected [72, 73] . The incidence of negative resection margins has been high; in some cases figures of 82% to 90% are reported [71] . These results may due to other factors, such as obtaining fine detail of the tumor preoperatively using spiral CT/angiography and the use of standardized surgical techniques. The survival results of preoperative chemoradiation seem initially to be encouraging, with median survival times of 19 months; but there are few long-term survival figures available (Table 5) . A recent nonrandomized study compared pre-and postoperative chemoradiotherapy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. Interestingly, there were no significant differences between the two groups of patients with respect to patterns of disease recurrence, and the median survival times were 19.2 months for the preoperative chemotherapy group and 22 months for the postoperative group [76] . Toxicity in this trial was similar in the two groups, but in other studies it has been considerable, requiring hospitalization. In view of the last study, the use of neoadjuvant therapy remains to be confirmed in a randomized trial before it can be endorsed as a standard treatment for pancreatic cancer. 
Adjuvant Combination Therapy
Following the promising results of the GITSG study of advanced pancreatic cancer, a randomized trial of postoperative therapy based on a similar protocol was commenced in 1973 [77] . Patients received 40 Gy combined with 5-FU or no adjuvant treatment. Initially 43 patients were entered, and the median survival in the treated group was 20 months compared to 11 months in the control group; the 2-year survival rates were 42% and 15%, respectively. Larger numbers were needed, so another 30 patients were treated; the median survival in this group was 18 months with a 2-year survival rate of 46% [78] . Additional adjuvant studies have been undertaken to demonstrate improved survival (Table 6), but large randomized trials are needed. A recent nonrandomised prospective study [79] compared (1) 40 Gy plus weekly 5-FU for 4 months with EBRT (50 -57 Gy), (2) hepatic irradiation (23-27 Gy) plus 5-FU and folinic acid, and (3) no treatment all at a single institution. Ninety-nine patients received the "standard" regimen, and the median survival in this group was 21 months; the 2-year survival was 44%. These figures were significantly longer than the no-treatment group median survival of 13.5 months and 2-year survival of 30%. Patients receiving the more intensive treatment showed no significant difference in survival from those in the "standard" treatment group (median survival 17.5 months; and 2-year survival 22%).
The UK Pancreatic Cancer Trials Group (UKPACA) studied combined treatment in 40 patients between 1987 and 1993 [80] . Following a potentially curative resection, treatment consisted of EBRT 40 Gy (with concomitant 5-FU) plus weekly courses of 5-FU for a maximum of 24 months. Altogether 36 patients managed to complete treatment, and 8% of these patients completed 12 months of chemotherapy. The median survival was 23 months, and the 5-year survival rate was 15%. Patients with positive lymph nodes had a significantly shorter survival time than those without lymph node involvement (Fig. 1) . A positive resection margin was associated with reduced survival on multiple regression analysis using lymph node status (Fig. 2) . The survival figures compared favorably with other studies, and the use of long-term chemotherapy was well tolerated.
The preliminary results of the EORTC phase III trial [65] call the role of radiotherapy into question, and its use remains to be confirmed in a larger randomized trial organized by the European Study Group for Pancreatic Cancer (ESPAC). This is the largest trial so far and has recruited almost 400 patients to date. The trial compares adjuvant EBRT 40 Gy (plus 5-FU) with systemic follow-on chemotherapy (folinic acid followed by 5-FU for 6 months) and a combination of these treatments with a control group [81] . It was anticipated that the trial would finish recruiting at the end of 1998. Additional studies are being formulated by ESPAC to assess different treatment modalities, such as regional chemotherapy and newer agents following surgery. These trials will provide a sound basis for the future choice of adjuvant therapy for patients with pancreatic cancer. 
Future Perspectives
A number of promising new agents have been developed whose action relies on knowledge of the biology and activity of pancreatic cancer, and they are currently being assessed in patients with advanced pancreatic cancer ( Table 7) . Hormonal agents such as tamoxifen have been used to treat pancreatic cancer without significant benefit, but the pure androgen receptor-blocking drug flutamide shows some promise. A controlled trial of flutamide versus placebo in advanced pancreatic cancer resulted in a median survival time of 8 months for patients taking flutamide compared to 4 months in the placebo group; the 1-year survivals were 33% and 4% in the respective groups (B. Greenway, personal communication). Immunotherapeutic agents such as cytotoxic monoclonal antibodies and cytokines have yet to show significant activity [90 -92] . Agents that cause DNA damage and replication arrest, such as thymidylate synthase inhibitors (folate enzyme inhibitors), are currently in phase I and II studies, as are topoisomerase I inhibitors [82, 83, 93] . The taxane family of compounds bind to tubulin and affect microtubule polymerization; so far paclitaxel has been used to limited effect in pancreatic cancer in combined approaches [84] . Strategies that inhibit tumor angiogenesis offer a novel way to inhibit tumor growth. Angiogenesis inhibitors, such as TNP-470 and interleukin-12 (IL-12), are currently being assessed in early clinical studies [86, 94, 95] . The orally bioavailable matrix metalloproteinase inhibitor marimastat (BB2516), which also acts as an angiogenesis inhibitor, has shown promising results in a phase II trial with a median survival time of more than 7 months in patients with unresectable stage II/III disease [87, 96] . A phase IIb study comparing the use of three different doses of marimastat with gemcitabine has recently finished recruiting patients, and the results will be available in the future. A phase III study to compare gemcitabine and marimastat with gemcitabine and placebo in patients with advanced pancreatic cancer should provide interesting results, as this treatment combines cytostatic and cytotoxic agents. Vaccination using Ras peptide has been assessed in a phase I/II trial, and in two of the five patients an immune response was induced [88] . Preclinical approaches using gene therapy are likely to lead to clinical trials in the near future [89, 97, 98] .
The next major adjuvant therapy trial organized by ESPAC (ESPAC-3) was due to commence at the end of 1998. The aims were to identify the most effective chemotherapeutic agent for use in the adjuvant setting. The encouraging results seen with gemcitabine and marimastat in advanced pancreatic cancer have prompted their use in ESPAC-3. The treatment groups consist of 5-FU/folinic acid (as the current standard) Ϯ gemcitabine. The proliferation of ongoing activity in this area confirms the importance of identifying a consistently effective adjuvant therapy for pancreatic cancer.
Résumé
Le cancer du pancréas représente une cause majeure de décès par tumeur maligne. En dépit des progrès en chirurgie et les soins en général, la survie médiane et à long terme ne se sont pas améliorées. La chirurgie radicale, seule, n'offre aucune garantie de cure. Des travaux antérieurs concernant la chimiothérapie conventionnelle et la radiothérapie chez les patients ayant un cancer avancé du pancréas, réséqué, sont en faveur d'un rôle positif de la thérapie adjuvante. Les modalités thérapeutique majeures, utilisant la chimiothérapie par le 5-fluorouracil et/ou la radiothérapie par bombe à colbalt, sont basées sur les résultats d'un groupe de travail nommé le «Gastrointestinal Tumor Study Group (GITSG)». Une approche alternative comme la thérapie néoadjuvante pourrait augmenter le nombre de patients chez lesquels une résection secondaire est réalisable. Des techniques régionales spécifiques sont utilisées pour augmenter la concentration des agents dans le lit tumoral. Les résultats de la thérapie simple ou combinée montrent une amélioration en ce qui concerne la survie mais ce sont, dans une large majorité des cas, des résultats d'études non-randomisées, rétrospectives et ainsi, ces résultats doivent être interprétés comme tels. Il y a, cependant, plusieurs grands essais randomisés qui devraient nous donner une réponse définitive dans l'avenir proche en ce qui concerne l'efficacité de la chimiothérapie adjuvante conventionnelle. De nouvelles approches, en utilisant de nouveaux agents en cas de maladie avancée, sont actuellement en voie d'évaluation et pourraient éventuellement identifier les agents les plus appropriés et les plus efficaces en ce qui concerne le traitement adjuvant du cancer du pancréas.
Resumen
La primacía, dentro de la mortalidad por cáncer, corresponde al de páncreas. A pesar de los avances realizados, tanto por lo que a la técnica quirúrgica se refiere como por lo que a la reanimación de estos pacientes atañe, la supervivencia a medio y largo plazo prácticamente no se ha modificado. Trabajos previos, sobre el tratamiento del cáncer avanzado de páncreas, utilizando quimioterapia y radioterapia convencional, apuntaron el posible papel de la terapia adyuvante en cánceres resecables. Las principales modalidades de esta terapia se basan en los resultados GDEPT: gene-directed enzyme-prodrug therapy obtenidos por el grupo de estudio de tumores gastrointestinales (GITSG) empleando el 5-fluorouracilo y/o la radioterapia externa (EBRT). Propuestas alternativas tales como la terapia neoadyuvante han permitido incrementar el número de pacientes susceptibles de resección quirúrgica; mediante el tratamiento loco-regional se pretende aumentar el potencial terapéutico al concentrar los agentes anticancerígenos en el lecho tumoral. Estas terapias aisladas o combinadas parece que han mejorado algo la supervivencia, pero la mayoría de los trabajos realizados al respecto son retrospectivos y no randomizados, por lo que su fiabilidad es discutible. Sin embargo, actualmente se están realizando estudíos randomizados, que cuando finalicen, constatarán o no, definitivamente, la eficacia de la terapia adyuvante. Además, se está investigando la acción de nuevos agentes quimioterápicos sobre el tratamiento del cáncer avanzado del páncreas; lo que tal vez permita identificar a aquellos cuya combinación sea más eficaz para el tratamiento adyuvante del cáncer de páncreas.
